Stanley-Laman Group’s BioLife Solutions BLFS Stock Holding History

Stanley-Laman Group’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-258,638	Closed	-$9.64M	–	279
2021 Q4	$9.64M	Buy	+258,638	New	+$11.1M	1.13%	25

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stanley-Laman Group's BLFS Position: Q1 2022 in Review

Stanley-Laman Group sold out of BioLife Solutions (BLFS) in Q1 2022, closing a stake of 258,638 shares — an estimated $9.64M sold.

Stanley-Laman Group first reported a position in BLFS in Q4 2021 and held it in 1 quarter. The position peaked at $9.64M in Q4 2021. 164 funds tracked by Wall St. Rank hold BLFS as of Q1 2022.

Stanley-Laman Group reported no remaining BioLife Solutions position as of Q1 2022 after selling out during the quarter.
Stanley-Laman Group sold 258,638 BioLife Solutions shares in Q1 2022, an estimated $9.64M.
Stanley-Laman Group first reported a position in BioLife Solutions in Q4 2021 and held it in 1 quarter.
Stanley-Laman Group's BioLife Solutions position peaked at $9.64M in Q4 2021.
164 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2022.

Based on Stanley-Laman Group's 13F filing for Q1 2022, filed 21 Apr 2022.